Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report.
JNMA J Nepal Med Assoc
; 59(238): 593-596, 2021 Jul 01.
Article
in English
| MEDLINE | ID: covidwho-1310357
ABSTRACT
Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
JNMA J Nepal Med Assoc
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS